✦ LIBER ✦

Guest editorial: role of monoclonal antibodies for the prevention and treatment of graft-versus-host disease

✍ Scribed by Yoshinobu Kanda

Book ID: 107619310
Publisher: Carden Jennings Publishing
Year: 2011
Tongue: English
Weight: 103 KB
Volume: 93
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-011-0866-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab for prevention and treatment o

Rituximab for prevention and treatment of graft-versus-host disease

✍ Mohamed A. Kharfan-Dabaja; Corey S. Cutler 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 179 KB

Alemtuzumab for the prevention and treat

Alemtuzumab for the prevention and treatment of graft-versus-host disease

✍ Junya Kanda; Richard D. Lopez; David A. Rizzieri 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 188 KB

Antibody incubation of human marrow graf

Antibody incubation of human marrow graft for prevention graft versus host disease

✍ Haas, R. J. ;Janka, G. ;Netzel, B. ;Rodt, H. ;Thierfelder, S. ;Helmig, M. ;Eife, 📂 Article 📅 1980 🏛 Springer-Verlag ⚖ 579 KB

New Strategies for Prevention and Treatm

New Strategies for Prevention and Treatment of Graft-versus-Host Disease and for Induction of Graft-versus-Leukemia Effects

✍ H. Joachim Deeg 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 98 KB

IFN-γ activation of mesenchymal stem cel

IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

✍ David Polchert; Justin Sobinsky; GW Douglas; Martha Kidd; Ada Moadsiri; Eduardo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB

In vivo CAMPATH-1 monoclonal antibodies:

In vivo CAMPATH-1 monoclonal antibodies: A novel mode of therapy for acute graft-versus-host disease

✍ Varadi, Gabor; Or, Reuven; Slavin, Shimon; Nagler, Arnon 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

CHOP, COP plui doxorubicin. ,'According to NCI criteria (Cheson el al. 151). (PD) was registered in one patient. Median time to disease progression for patients in PR or SD was 9 months (range, 1-14 months) (Table I). The results of the prehent study, although based on a small number of patients,